24 results on '"Exeni, I."'
Number of results to display per page
Search Results
2. AB1666 CLUSTER ANALYSIS TO IDENTIFY PATIENT GROUPS AND ASSESS THE PRESENCE OF ADVERSE EVENTS. REAL WORLD EVIDENCE FROM THE BIOBADASAR 3.0 REGISTRY
- Author
-
Brigante, J. A., primary, Roberts, K., additional, Isnardi, C., additional, Gómez, G., additional, Haye, M., additional, García, M., additional, Gobbi, C., additional, Casado, G., additional, Holguín Arias, L. L., additional, Dapeña, J. M., additional, Papasidero, S., additional, Berbotto, G., additional, Viola, M., additional, Saurit, V., additional, Petkovic, I., additional, Bertoli, A., additional, Diaz, M. P., additional, Catay, E., additional, Exeni, I. E., additional, Pons-Estel, B., additional, Bovea Castelblanco, G., additional, De La Sota, M. E., additional, Larroude, M. S., additional, Pereira, D. A., additional, Granel, A. B., additional, Medina, G., additional, Pisoni, C., additional, Sacnun, M., additional, Velozo, E., additional, Aste, N., additional, Castro, C., additional, Kerzberg, E., additional, Savio, V., additional, Gamba, J., additional, Secco, A., additional, Citera, G., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and De la Vega, M., additional
- Published
- 2023
- Full Text
- View/download PDF
3. POS0655 SURVIVAL AND SAFETY OF BIOLOGICAL AND TARGETED SYNTHETIC THERAPIES AS REGARDS TO AGE GROUPS. BIOBADASAR 3.0 REGISTRY.
- Author
-
Brigante, A., primary, Isnardi, C. A., additional, Gómez, G., additional, Quintana, R., additional, Haye, M., additional, Roberts, K., additional, García, M., additional, Gomez, G., additional, Gobbi, C., additional, Casado, G., additional, Rebak, J., additional, Dapeña, J. M., additional, Berbotto, G., additional, Viola, M., additional, Saurit, V., additional, Petkovic, I. E., additional, Bertoli, A., additional, Giorgis, P., additional, Diaz, M. P., additional, Catay, E., additional, Exeni, I. E., additional, Pons-Estel, B., additional, Paira, S., additional, Bovea Castelblanco, G., additional, De La Sota, M. E., additional, Larroude, M. S., additional, Pereira, D. A., additional, Granel, A. B., additional, Medina, G., additional, Pisoni, C., additional, Alvarez, A., additional, Aguero, S. E., additional, Fernandez, L., additional, Sacnun, M., additional, Soares de Souza, S., additional, Velozo, E., additional, Aste, N., additional, Castro, C., additional, Lazaro, A., additional, Kerzberg, E., additional, Gallardo, M. D. L. Á., additional, Savio, V., additional, Gamba, J., additional, Secco, A., additional, Citera, G., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and Delavega, M., additional
- Published
- 2022
- Full Text
- View/download PDF
4. POS1199 IS PSORIATIC ARTHRITIS A RISK FACTOR FOR SEVERE COVID -19 INFECTION? DATA FROM THE ARGENTINIAN REGISTRY SAR-COVID
- Author
-
Savio, V., primary, Maldini, C., additional, Alba, P., additional, Saurit, V., additional, Berbotto, G., additional, Pisoni, C., additional, Tissera, Y., additional, Nieto, R., additional, Maldonado, F., additional, Ornella, S., additional, Gobbi, C., additional, Baños, A. R., additional, Vivero, F., additional, Exeni, I. E., additional, Cusa, A., additional, Bellomio, V. I., additional, Perez Alamino, R., additional, Gomez, G., additional, Zelaya, D., additional, Risueño, F., additional, Quaglia, M. I., additional, Correa, M. D. L. A., additional, Rojas Tessel, R., additional, Delavega, M., additional, Lazaro, M. A., additional, Mercé, A. L., additional, Finucci, P., additional, Matellan, C. E., additional, Romeo, C., additional, Martire, V., additional, Moyano, S., additional, Martin, M. L., additional, Picco, E., additional, Goizueta, C., additional, Tralice, E. R., additional, Tamborenea, M. N., additional, Subils, G. C., additional, Gallo, R., additional, Pineda Vidal, S. I., additional, Velasco Zamora, J. L., additional, Lloves Schenone, N., additional, Cosentino, V., additional, Rodriguez, F., additional, Diaz, M. P., additional, Viola, M., additional, Mamani Ortega, M. L., additional, Buschiazzo, E., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, Isnardi, C. A., additional, and Pons-Estel, G., additional
- Published
- 2022
- Full Text
- View/download PDF
5. AB1101 PREVALENCE OF LONG COVID IN RHEUMATIC DISEASE PATIENTS: ANALYSIS OF SAR COVID REGISTRY
- Author
-
Gonzalez Gomez, C. A., primary, Cosatti, M., additional, Castro Coello, V. V., additional, Haye, M., additional, Tissera, Y., additional, Reyes, A. A., additional, Albiero, J. A., additional, Ornella, S., additional, Alba, P., additional, Gobbi, C., additional, Gamba, M. J., additional, Exeni, I. E., additional, Cusa, A., additional, Gallino Yanzi, J., additional, Bellomio, V. I., additional, Gomez, G., additional, Zelaya, D., additional, Takashima, L., additional, Carlevaris, L., additional, Correa, M. D. L. A., additional, Rojas Tessel, R., additional, García, M., additional, German, N., additional, Mercé, A. L., additional, Bertoli, A., additional, Aguero, S. E., additional, Calvo, M. E., additional, Martire, V., additional, Mauri, M., additional, Martin, M. L., additional, Picco, E., additional, Castrillon Bustamante, D., additional, Ibañez Zurlo, L., additional, Tamborenea, M. N., additional, Subils, G. C., additional, Vasquez, D. L., additional, Soares de Souza, S., additional, Herscovich, N., additional, Raiti, L., additional, Cosentino, V., additional, Rodriguez, F., additional, Ledesma, C., additional, Diaz, M. P., additional, Mamani Ortega, M. L., additional, Castaño, M. S., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, Isnardi, C. A., additional, Pons-Estel, G., additional, and Pisoni, C., additional
- Published
- 2022
- Full Text
- View/download PDF
6. AB1094 SAFETY AND EFFICACY OF VACCINES FOR SARS-CoV-2 IN PATIENTS WITH RHEUMATIC AND IMMUNE-MEDIATED INFLAMMATORY DISEASES: DATA FROM THE ARGENTINEAN REGISTRY SAR-CoVAC
- Author
-
Isnardi, C. A., primary, Roberts, K., additional, Quintana, R., additional, Kreimer, J., additional, Echeverria, C., additional, Luna, P. C., additional, Virasoro, B. M., additional, Exeni, I. E., additional, Kogan, N., additional, Correa, M. D. L. A., additional, Pereira, D. A., additional, Zelaya, D., additional, Tissera, Y., additional, Pisoni, C., additional, Gálvez Elkin, M. S., additional, Alonso, C. G., additional, Cogo, A. K., additional, Cosatti, M., additional, Garcia, L., additional, Retamozo, C., additional, Severina, M., additional, Nieto, R., additional, Rosemffet, M., additional, Mussano, E. D., additional, Bertoli, A., additional, Delavega, M., additional, Savio, V., additional, Cosentino, V., additional, Roldan, B., additional, Maldonado Ficco, H., additional, Maid, P., additional, Calle Montoro, C., additional, Fernandez, L., additional, Leguizamón, M. L., additional, Gómez Vara, A. B., additional, Alfaro, M. A., additional, Landi, M., additional, Herscovich, N., additional, Maldini, C., additional, De la Vega Fernandez, S. S., additional, Velozo, E., additional, Giorgis, P., additional, Sattler, M. E., additional, Reyes Gómez, C., additional, Perrotat, L., additional, Reimundes, C., additional, Ezquer, R. A., additional, Saurit, V., additional, Flores Trejo, J., additional, Cerda, O. L., additional, Crespo Rocha, M. G., additional, Carrizo Abarza, V., additional, Strusberg, I., additional, Rojas Tessel, R., additional, Verna, G., additional, Bande, J. M., additional, Farfan, P., additional, Berbotto, G., additional, Pons-Estel, G., additional, and Schneeberger, E. E., additional
- Published
- 2022
- Full Text
- View/download PDF
7. CLUSTER ANALYSIS TO IDENTIFY PATIENT GROUPS AND ASSESS THE PRESENCE OF ADVERSE EVENTS. REAL WORLD EVIDENCE FROM THE BIOBADASAR 3.0 REGISTRY.
- Author
-
Brigante, J. A., Roberts, K., Isnardi, C., Gómez, G., Haye, M., García, M., Gobbi, C., Casado, G., Arias, L. L. Holguín, Dapeña, J. M., Papasidero, S., Berbotto, G., Viola, M., Saurit, V., Petkovic, I., Bertoli, A., Diaz, M. P., Catay, E., Exeni, I. E., and Pons-Estel, B.
- Published
- 2023
- Full Text
- View/download PDF
8. Sexto reporte de eventos adversos con tratamientos biológicos en Argentina: Informe del registro BIOBADASAR
- Author
-
Gómez, G., Pons-Estel, G., Citera, G., Soriano, E., Saurit, V., Benavidez, F., Velozo, E., Dubinsky, D., Exeni, I., Gobi, C., Díaz, M., Granel, A., Smichowsky, A., Garate, G., Quinteros, A., Cavillon, E., Petkovic, I., Larroude, M.S., de la Sota, M., Cappuccio, A.M., Berbotto, G., Alvarez, A., Papasidero, S., Lazaro, A., Garcia, M., Sacnun, M., Soares de Souza, S., Bertoli, A., Bejarano, V., Rillo, O., Kerzberg, E., Quintana, R., Agüero, S., Somma, L., Cruzat, V., Battaglitti, C., Perez Dávila, A., Gallardo, M., Pereira, D., Verando, M., Paira, S., Martinez, L., Aste, N., Pisoni, C., Catay, E., Graf, C., Casado, G., and de la Vega, M.
- Subjects
registro ,register ,biologics ,eventos adversos ,biológicos ,adverse events - Abstract
Objetivo: Actualizar los resultados del registro BIOBADASAR sobre seguridad, duración y causas de interrupción del tratamiento luego de 8 años de seguimiento. Métodos: BIOBADASAR es un registro de seguridad de terapias biológicas establecido por la Sociedad Argentina de Reumatología. Se presenta la descripción de BIOBADASAR 3.0, una cohorte compuesta por 53 centros de Argentina seguidos prospectivamente desde agosto de 2010 hasta enero de 2018. Resultados: Se registraron 4656 pacientes, 6234 tratamientos [3765 casos (terapia con biológicos) y 2469 controles (terapia no biológicos)]. Se interrumpió el tratamiento en el 44,6% en los casos vs. 27,9% en los controles. Causa principal de discontinuación fue por ineficacia (40% casos vs. 32% controles). Se presentaron 3154 eventos adversos (2230 en casos vs. 924 en controles), de los cuales el 13,6% fueron graves (9,8% en casos y 3,7% en controles). El evento adverso (EA) más frecuente en ambos grupos fueron las infecciones (43,56% en casos vs. 34,31% en los controles, RR: 3,42; IC 95%: 3,02-3,88), y de ellas las de vías aéreas superiores (14,5%). Las neoplasias se presentaron en 78 casos vs. 45 en controles (RR: 1,98; IC 95%: 1,37-2,86). Conclusiones: En este sexto reporte no se observan tendencias diferentes sobre seguridad, duración y causas de interrupción del tratamiento respecto a informes previos. Las infecciones fueron el principal EA y la ineficacia, seguido por EA y la pérdida de pacientes las principales causas de suspensión del tratamiento. El advenimiento de nuevos agentes biológicos y la necesidad de control en seguridad a largo plazo, fortalece el uso de este tipo de registro. Objective: Update the results of the BIOBADASAR registry on safety, duration and causes of treatment interruption after 8 years of follow-up. Methods: BIOBADASAR is a safety record of biological therapies established by the Argentine Society of Rheumatology. The description of BIOBADASAR 3.0 is presented, a cohort of 53 centers in Argentina followed prospectively from August 2010 to January 2018. Results: 4656 patients were registered, 6234 treatments [3765 cases (therapy with biologicals) and 2469 controls (non-biological therapy)]. Treatment was interrupted in 44.6% in cases vs. 27.9% in controls. Main cause of discontinuation was due to inefficiency (40% cases vs. 32% controls). There were 3154 adverse events (2230 in cases vs. 924 in controls), of which 13.6% were tombs (9.8% in cases and 3.7% in controls). The most frequent adverse event (AE) in both groups were infections (43.56% in cases vs. 34.31% in controls, RR: 3.42, 95% CI: 3.02-3.88), and the upper airway pathways (14.5%). Neoplasms were published in 78 cases versus 45 controls (RR: 1.98, 95% CI: 1.37-2.86). Conclusions: In this article, there are no different trends regarding safety, duration and causes of interruption of treatment compared to previous reports. Infections were the main causes of treatment discontinuation. The advent of new biological agents and the need for control over long-term security, strengthens the use of this type of registration.
- Published
- 2019
9. Sixth report of adverse events with biological treatments in Argentina. BIOBADASAR registry report
- Author
-
Gómez, G., primary, Pons-Estel, G., additional, Citera, G., additional, Soriano, E., additional, Saurit, V., additional, Benavidez, F., additional, Velozo, E., additional, Dubinsky, D., additional, Exeni, I., additional, Gobi, C., additional, Gómez, G., additional, Díaz, M., additional, Granel, A., additional, Smichowsky, A., additional, Garate, G., additional, Quinteros, A., additional, Cavillon, E., additional, Petkovic, I., additional, Larroude, M.S., additional, de la Sota, M., additional, Cappuccio, A.M., additional, Berbotto, G., additional, Alvarez, A., additional, Papasidero, S., additional, Lazaro, A., additional, Garcia, M., additional, Sacnun, M., additional, Soares de Souza, S., additional, Bertoli, A., additional, Bejarano, V., additional, Rillo, O., additional, Kerzberg, E., additional, Quintana, R., additional, Agüero, S., additional, Somma, L., additional, Cruzat, V., additional, Battaglitti, C., additional, Perez Dávila, A., additional, Gallardo, M., additional, Pereira, D., additional, Verando, M., additional, Paira, S., additional, Martinez, L., additional, Aste, N., additional, Pisoni, C., additional, Catay, E., additional, Graf, C., additional, Casado, G., additional, and de la Vega, M., additional
- Published
- 2019
- Full Text
- View/download PDF
10. THU0619 Prevalence of pneumococcal vaccination in rheumatologic patients with community acquired pneumonia. biobadasar registry
- Author
-
Gόmez, G, primary, Brigante, A, additional, Benitez, A, additional, Cerda, O, additional, Retamozo, S, additional, Gandino, I, additional, Quinteros, A, additional, Exeni, I, additional, Barrios, B, additional, Astesana, P, additional, Andia, C Sanchez, additional, Collado, MV, additional, Granel, A, additional, Cappuccio, AM, additional, Quintana, R, additional, Mussano, E, additional, Smichowski, A, additional, Sota, M de la, additional, Kirmayr, K, additional, Velozo, E, additional, Larroude, MS, additional, Bertoli, A, additional, Agüero, S, additional, Battagliotti, C, additional, Souza, S Soaures de, additional, Cavillon, E, additional, Bohr, A, additional, Rillo, O, additional, Carlevaris, L, additional, Bedoya, E, additional, Kerzberg, E, additional, Kisluk, B, additional, Petkovic, I, additional, Pereira, D, additional, Barreira, JC, additional, Somma, L, additional, Costi, C, additional, Melo, F, additional, Virasoro, B, additional, Paira, S, additional, Perez, L Roa, additional, Casado, G, additional, and Celina, DLV María, additional
- Published
- 2017
- Full Text
- View/download PDF
11. CARDIOVASCULAR OUTCOMES OF ANTI-TNF ALFA AND JAK INHIBITORS IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS. REAL WORLD EVIDENCE AND INSIGHTS OF BIOBADASAR 3.0 REGISTRY.
- Author
-
Brigante, J. A., Roberts, K., Isnardi, C. A., Gómez, G., Holguín Arias, L. L., Pons-Estel, B., Gamba, J., Haye, M., Dapeña, J. M., Secco, A., Savio, V., Soliz Cordero, C., Gobbi, C., Velozo, E., Catay, E., Aste, N., Medina, G., Exeni, I. E., Gomez, G., and Pereira, D. A.
- Published
- 2023
- Full Text
- View/download PDF
12. SAT0488 Tuberculosis in A Registry of Rheumatic Patients Treated with Biological Drugs
- Author
-
Benzaquén, N., primary, Haye Salinas, M., additional, Pirola, J., additional, Retamozo, S., additional, Caeiro, F., additional, Alvarellos, A., additional, De la Vega, M., additional, Casado, G., additional, Gomez, G., additional, Citera, G., additional, Gallardo, M., additional, Quinteros, A., additional, Exeni, I., additional, Medina, M., additional, Astesana, P., additional, Sanchez Andia, C., additional, Sarano, J., additional, Granel, A., additional, Peluzzon, A., additional, Cappucciona, A., additional, Eimon, A., additional, Quintana, R., additional, Pons Estel, B., additional, Mussano, E., additional, Scarafia, S., additional, Tamaño, F., additional, Costi, C., additional, De la Sota, M., additional, Kirmayr, K., additional, Velozo, E., additional, Ortiz, A., additional, Larroudé, M., additional, Bertoli, A., additional, Aguero, S., additional, Battagliotti, C., additional, Soares de Souza, S., additional, Cavillon, E., additional, Perez Dávila, A., additional, Barreira, J., additional, Roberti, J., additional, and Saurit, V., additional
- Published
- 2016
- Full Text
- View/download PDF
13. Características de los tratamientos biológicos en enfermedades reumáticas en Argentina: quinto informe del registro BIOBADASAR
- Author
-
De la Vega, M., primary, Casado, G., additional, Roberti, J., additional, Gómez, M.G., additional, Benítez, A., additional, Battagliotti, C., additional, Exeni, I., additional, Gobbi, C., additional, Astesana, P., additional, Quintana, R., additional, Bertoli, A., additional, Strusberg, I., additional, Paira, S., additional, Mussano, E., additional, Vidal, D., additional, Rama, M., additional, Cavillon, E., additional, Quinteros, A., additional, Capuccio, A., additional, Bovea, G., additional, De la Sota, M., additional, Larroudé, M., additional, Granel, A., additional, Marcos, A., additional, Smichowski, A., additional, Tamaño, F., additional, Barrios, B., additional, Bande, J.M., additional, Soriano, E., additional, Eimon, A., additional, Alvarez, A., additional, Gomez, G., additional, Agüero, S., additional, Sacnun, M., additional, Garcia, M., additional, Costi, C., additional, Soares de Souza, S., additional, Velozo, E., additional, Diaz, M., additional, Sarano, J., additional, Pons-Estel, B., additional, Saurit, V., additional, Miretti, E., additional, Dubinsky, D., additional, Perez Davila, A., additional, Bohr, A., additional, Mamani, M., additional, Scarafia, S., additional, Sanchez Andia, C., additional, Kirmayr, K., additional, Barreira, J.C., additional, and Citera, G., additional
- Published
- 2016
- Full Text
- View/download PDF
14. [Ventricular diastolic dysfunction in rheumatoid arthritis]
- Author
-
Lascano C, Alba P, Carla Andrea Gobbi, Videla F, Campos F, Sosa H, Babini A, Exeni I, and Albiero E
- Subjects
Arthritis, Rheumatoid ,Male ,Ventricular Dysfunction, Left ,Cross-Sectional Studies ,Case-Control Studies ,Heart Ventricles ,Humans ,Female ,Age of Onset ,Middle Aged ,Echocardiography, Doppler - Abstract
Rheumatoid arthritis ( RA) is a chronic and systemic articular inflammatory disease, often associated with cardiac manifestations. However, cardiac involvement in RA is not always symptomatic. Previous studies reported high mortality rates for RA and that it was dependent on concurrent heart dis-ease. Myocardial infarction and inflammation have been reported in about 2% of the patients in autopsy studies. The earliest deterioration in cardiac disease is in diastolic function.the aim of this study is to evaluate the ventricular diastolic dysfunction in patients with RA and its relation with the duration of the disease.Thirty-two RA patients who attended the rheumatology unit at Hospital Cordoba during 2004 participated in this study. A control group was formed by thirty two healthy adults of matched sex and age. RA was diagnosed according to 1987 ACR criteria. None of them had diabetes mellitus, systemic hypertension, chronic lung disease, congenital cardiac malformation, coronary artery disease, arrhytmia or valvular heart disease. Two-dimensional, M-mode, pulsed and color Doppler echocardiography were performed on all these subjects by the same examiner. Diastolic dysfunction was defined when the E/A ratio was1 (E wave velocity decreased, A wave velocity increased) , and desaceleration time (DT) and isovolumic relaxation time (IRT) were prolonged. Ap-value0.05 was considered as significant.The mean ages were 48,38 11,08 for patients and 46,81 9,96 for the control group.There were no significant differences between age, sex, heart rate, and systolic and diastolic blood pressure between RA patients and controls. Higher proportion of RA patients had E/A ratio1compared with the controls ( p00001). The mean IRT value was significantly longer than in controls ( 83,59 1 13,82 vs 74,41 i 15,14 p0.01). There was no correlation between the duration of illness and E/A ratio and IRT ( p=0.70, p=0.13).Diastolic function was impaired in patients with RA. There was no relation between some of the parameters of ventricular diastolic function and disease duration. These findings suggest a subclinical myocardial involvement in RA patients.
- Published
- 2010
15. [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis]
- Author
-
Nesa L, Carla Andrea Gobbi, Alba P, Exeni I, Babini A, and Albiero E
- Subjects
Male ,Administration, Oral ,Isoxazoles ,Middle Aged ,Injections, Intramuscular ,Arthritis, Rheumatoid ,Methotrexate ,Treatment Outcome ,Antirheumatic Agents ,Humans ,Drug Therapy, Combination ,Female ,Epidemiologic Methods ,Leflunomide ,Retrospective Studies - Abstract
Rheumatoid Arthritis (RA) is a chronic disease leading to functional impairment and early mortality. Treatment with disease-modifying antirheumatic drugs have shown to achieve disease remission and improves its evolution. The use of combined therapy should have a biological efficacy, no increased toxicity and have an acceptable dose interval. Also, it should begin its action quickly and be cost-effective.to assess the security of the combined treatment with Methotrexate (MTX) and Leflunomide (LF) in patients with Rheumatoid Arthritis (RA) and to evaluate whether the dose and route of MTX administration influence on the toxicity.Patients with RA who fulfilled ACR criteria and they attended to the Rheumatology Unit at Córdoba Hospital in the last 2 years were assessed. All the patients that received combined treatment with MTX in doses from 7.5 mg to 25 mg weekly orally (PO) or intramuscularly (i.m.) that started LF treatment in doses of 20 mg/day due to disease activity persistence were retrospectively assessed. Patients having at least 6 months of combined treatment were included. Data on treatment and adverse events were collected. They were evaluated at the beginning, at 6 and 12 months of treatment. The presence of adverse events as well as the stop of combined treatment was evaluated at 6 and 12 months of treatment. Adverse events in patients with oral and i.m. MTX treatment and in different doses were compared for the analyses. P0.05 was considered significant.62 patients with a mean age of 54 were included. 89% were female and had positive rheumatoid factor and 83% had radiological erosions. Eighty eight percent were in doses of 15 mg MTX, 4.9% with 10 mg and 25 mg at the beginning of LF treatment. Twenty four percent suffered from adverse events and 33% left the medication by 6 months. Among adverse events, 6 patients had diarrhea, 5 increased hepatic enzymes, 3 alopecia, 3 weight loss, and 2 had anemia and leucopenia. Eight patients stopped the medication in 6 months, but only 5 did because of adverse events. There was not significant statistical difference in adverse events between patients with different dose or routes of administration of MTX.The presence of adverse events in MTX and LF combined treatment was low and it developed during the first 6 months of treatment in our patients. The MTX route of administration and doses did not influence on the toxicity of the combined treatment with LF. The combined therapy seems to be a safe treatment option in RA patients.
- Published
- 2009
16. AB1075 Argentinian Register of BIOLOGICS Treatments (BIOBADASAR). Results
- Author
-
Gomez, M.G., primary, de la Vega, M.C., additional, Casado, G., additional, Exeni, I., additional, Gobbi, C., additional, Quintana, R., additional, Pons Estel, B., additional, Bertoli, A., additional, Miretti, E., additional, Saurit, V., additional, Paira, S., additional, Mussano, E., additional, Vidal, D., additional, Quinteros, A., additional, Cappuccio, A.M., additional, de la Sota, M., additional, Larroudé, M., additional, Granel, A., additional, Rillo, O.L., additional, Quiroz, C., additional, Dubinsky, D., additional, Oliver, M., additional, Eimon, A., additional, Alvarez, A., additional, Gόmez, G., additional, Agüero, S., additional, Smichowski, A., additional, Battagliotti, C., additional, Sacnun, M., additional, Garcia, M., additional, Soares de Souza, S., additional, Velozo, E., additional, Caprarulo, C., additional, Díaz, M., additional, Schneeberger, E., additional, Soriano, E., additional, and Citera, G., additional
- Published
- 2014
- Full Text
- View/download PDF
17. Tercer reporte de eventos adversos con tratamientos biológicos en Argentina: informe de registro BIOBADASAR
- Author
-
de la Vega, M., Gómez, G., Casado, G., Battagliotti, C., Exeni, I., Gobbi, Carla, Quintana, R., Bertoli, A., Miretti, E., Paira, Sergio Oscar, Mussano, Eduardo, Vidal, D., Quinteros, A., Capuccio, A., de la Sota, M., Larroudé, M., Martinez Muñoz, A., Quir, C., de la Vega, M., Gómez, G., Casado, G., Battagliotti, C., Exeni, I., Gobbi, Carla, Quintana, R., Bertoli, A., Miretti, E., Paira, Sergio Oscar, Mussano, Eduardo, Vidal, D., Quinteros, A., Capuccio, A., de la Sota, M., Larroudé, M., Martinez Muñoz, A., and Quir, C.
- Abstract
BIOBADASAR ((Registro Argentino de Eventos Adversos con Tratamientos Biológicos en Reumatología) comenzó en agosto de 2010. La importancia de este registro es mostrar datos locales que, probablemente, puedan diferir de otros registros. El objetivo es comunicar los resultados del tercer reporte de BIOBADASAR.
- Published
- 2013
18. Tercer reporte de eventos adversos con tratamientos biológicos en Argentina
- Author
-
De la Vega, M., primary, Gómez, G., additional, Casado, G., additional, Battagliotti, C., additional, Exeni, I., additional, Gobbi, C., additional, Quintana, R., additional, Bertoli, A., additional, Miretti, E., additional, Paira, S., additional, Mussano, E., additional, Vidal, D., additional, Quinteros, A., additional, Capuccio, A., additional, De la Sota, M., additional, Larroudé, M., additional, Martinez Muñoz, A., additional, and Quir, C., additional
- Published
- 2013
- Full Text
- View/download PDF
19. Factors associated with patients' loss to follow-up after finishing randomized clinical trial participation
- Author
-
STRUSBERG, I, primary, BERTOLI, A, additional, RAMOS, M, additional, FIERRO, G, additional, PIZZOLATO, R, additional, EXENI, I, additional, and STRUSBERG, A, additional
- Published
- 2004
- Full Text
- View/download PDF
20. [Bacterial endocarditis caused by salmonella in systemic lupus erythematosus].
- Author
-
Gobbi C, Alba P, Arvarellos A, Astesana P, Exeni I, Caeiro F, and Albiero E
- Subjects
- Adult, Endocarditis, Bacterial diagnosis, Fatal Outcome, Female, Humans, Middle Aged, Salmonella Infections diagnosis, Endocarditis, Bacterial microbiology, Lupus Erythematosus, Systemic complications, Salmonella Infections complications
- Abstract
Introduction: Patients with SLE (Systemic Lupus Erythematosus) are prompt to develop infections with significant morbidity and mortality. The intravascular infection due to salmonella is a rare complication of difficult diagnosis and poor prognostic., Objective: We report two cases of bacterial endocarditis due to salmonella in SLE patients., Clinical Cases: We report two cases of bacterial endocarditis caused by Salmonella in a patient with SLE, one with recent onset of mellitus diabetes and other with chronic renal failure. Despite of antibiotic treatment with fluoroquinolone and a third-generation cephalosporin, the patient required surgical intervention., Conclusion: Salmonella infection should be suspected in SLE patients in order to make earlier diagnosis and treatment.
- Published
- 2011
21. [Ventricular diastolic dysfunction in rheumatoid arthritis].
- Author
-
Lascano C, Alba P, Gobbi C, Videla F, Campos F, Sosa H, Babini A, Exeni I, and Albiero E
- Subjects
- Age of Onset, Arthritis, Rheumatoid complications, Case-Control Studies, Cross-Sectional Studies, Echocardiography, Doppler methods, Female, Heart Ventricles diagnostic imaging, Humans, Male, Middle Aged, Ventricular Dysfunction, Left diagnostic imaging, Arthritis, Rheumatoid physiopathology, Heart Ventricles physiopathology, Ventricular Dysfunction, Left physiopathology
- Abstract
Unlabelled: Rheumatoid arthritis ( RA) is a chronic and systemic articular inflammatory disease, often associated with cardiac manifestations. However, cardiac involvement in RA is not always symptomatic. Previous studies reported high mortality rates for RA and that it was dependent on concurrent heart dis-ease. Myocardial infarction and inflammation have been reported in about 2% of the patients in autopsy studies. The earliest deterioration in cardiac disease is in diastolic function., Objective: the aim of this study is to evaluate the ventricular diastolic dysfunction in patients with RA and its relation with the duration of the disease., Patients and Methods: Thirty-two RA patients who attended the rheumatology unit at Hospital Cordoba during 2004 participated in this study. A control group was formed by thirty two healthy adults of matched sex and age. RA was diagnosed according to 1987 ACR criteria. None of them had diabetes mellitus, systemic hypertension, chronic lung disease, congenital cardiac malformation, coronary artery disease, arrhytmia or valvular heart disease. Two-dimensional, M-mode, pulsed and color Doppler echocardiography were performed on all these subjects by the same examiner. Diastolic dysfunction was defined when the E/A ratio was <1 (E wave velocity decreased, A wave velocity increased) , and desaceleration time (DT) and isovolumic relaxation time (IRT) were prolonged. Ap-value < 0.05 was considered as significant., Results: The mean ages were 48,38 11,08 for patients and 46,81 9,96 for the control group.There were no significant differences between age, sex, heart rate, and systolic and diastolic blood pressure between RA patients and controls. Higher proportion of RA patients had E/A ratio < 1compared with the controls ( p<00001). The mean IRT value was significantly longer than in controls ( 83,59 1 13,82 vs 74,41 i 15,14 p<0.01). There was no correlation between the duration of illness and E/A ratio and IRT ( p=0.70, p=0.13)., Conclusion: Diastolic function was impaired in patients with RA. There was no relation between some of the parameters of ventricular diastolic function and disease duration. These findings suggest a subclinical myocardial involvement in RA patients.
- Published
- 2009
22. [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].
- Author
-
Nesa L, Gobbi C, Alba P, Exeni I, Babini A, and Albiero E
- Subjects
- Administration, Oral, Antirheumatic Agents administration & dosage, Drug Therapy, Combination adverse effects, Epidemiologic Methods, Female, Humans, Injections, Intramuscular, Isoxazoles administration & dosage, Leflunomide, Male, Methotrexate administration & dosage, Middle Aged, Retrospective Studies, Treatment Outcome, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid drug therapy, Isoxazoles adverse effects, Methotrexate adverse effects
- Abstract
Unlabelled: Rheumatoid Arthritis (RA) is a chronic disease leading to functional impairment and early mortality. Treatment with disease-modifying antirheumatic drugs have shown to achieve disease remission and improves its evolution. The use of combined therapy should have a biological efficacy, no increased toxicity and have an acceptable dose interval. Also, it should begin its action quickly and be cost-effective., Aims: to assess the security of the combined treatment with Methotrexate (MTX) and Leflunomide (LF) in patients with Rheumatoid Arthritis (RA) and to evaluate whether the dose and route of MTX administration influence on the toxicity., Patients and Methods: Patients with RA who fulfilled ACR criteria and they attended to the Rheumatology Unit at Córdoba Hospital in the last 2 years were assessed. All the patients that received combined treatment with MTX in doses from 7.5 mg to 25 mg weekly orally (PO) or intramuscularly (i.m.) that started LF treatment in doses of 20 mg/day due to disease activity persistence were retrospectively assessed. Patients having at least 6 months of combined treatment were included. Data on treatment and adverse events were collected. They were evaluated at the beginning, at 6 and 12 months of treatment. The presence of adverse events as well as the stop of combined treatment was evaluated at 6 and 12 months of treatment. Adverse events in patients with oral and i.m. MTX treatment and in different doses were compared for the analyses. P<0.05 was considered significant., Results: 62 patients with a mean age of 54 were included. 89% were female and had positive rheumatoid factor and 83% had radiological erosions. Eighty eight percent were in doses of 15 mg MTX, 4.9% with 10 mg and 25 mg at the beginning of LF treatment. Twenty four percent suffered from adverse events and 33% left the medication by 6 months. Among adverse events, 6 patients had diarrhea, 5 increased hepatic enzymes, 3 alopecia, 3 weight loss, and 2 had anemia and leucopenia. Eight patients stopped the medication in 6 months, but only 5 did because of adverse events. There was not significant statistical difference in adverse events between patients with different dose or routes of administration of MTX., Conclusions: The presence of adverse events in MTX and LF combined treatment was low and it developed during the first 6 months of treatment in our patients. The MTX route of administration and doses did not influence on the toxicity of the combined treatment with LF. The combined therapy seems to be a safe treatment option in RA patients.
- Published
- 2007
23. Factors associated with patients' loss to follow-up after finishing randomized clinical trial participation.
- Author
-
Strusberg I, Bertoli AM, Ramos M, Fierro G, Pizzolato R, Exeni I, and Strusberg AM
- Subjects
- Arthritis, Rheumatoid drug therapy, Cyclooxygenase Inhibitors therapeutic use, Female, Humans, Male, Matched-Pair Analysis, Middle Aged, Multivariate Analysis, Osteoarthritis drug therapy, Physician-Patient Relations, Retrospective Studies, Risk Factors, Statistics, Nonparametric, Patient Dropouts, Randomized Controlled Trials as Topic
- Abstract
Objectives: To study patient's follow-up after finishing participation in randomized clinical trials (RCTs), and to identify factors associated with loss to follow-up (FU)., Patients and Methods: Medical charts of 212 rheumatoid arthritis (RA) and osteoarthritis (OA) patients from a rheumatological out-patient center were analyzed. Loss to FU was considered when patients did not return to their regular appointments within the first year after finishing their participation in an RCT assessing anti-cyclooxygenase-2 non-steroidal anti-inflammatory drugs (anti-COX-2 NSAIDs). Mann-Whitney U-test, chi2 test and Wilcoxon test were performed as appropriate. Logistic regression was performed to identify factors which might be related to loss to FU. A survey was conducted to obtain lost to FU patients' opinions. p values less than 0.05 were considered significant., Results: The mean frequency of patients' visits in the year before enrollment in an RCT was 3.73 SD 2.06, and during the year after participation was 2.6 SD 1.96 (p<0.0001). Fifty patients (23.6%) did not return to their usual rheumatologic visit. On multivariate analysis, the number of daily tablets of study medication (odds ratio (OR)=2.64, 95% confidence interval (CI) 1.1 to 6.3) and the frequency of clinical visits (OR=0.56, 95% CI 0.37 to 0.85) were associated with loss to FU (p<0.008). Lost to FU patients' opinions did not support these findings., Conclusions: After participating in a RCT assessing anti-COX-2 NSAIDs, many patients return with less frequency, or do not return at all to their regular rheumatologic visit. Although a high number of tablets of the investigational drug and a low frequency of protocol visits may be contributors to patient loss to FU, investigators should consider that personal situations not related to the RCTs may also influence patients' return to consultation in the private setting.
- Published
- 2005
- Full Text
- View/download PDF
24. [Management of febrile monoarthritis].
- Author
-
Albiero EH and Exeni IE
- Subjects
- Arthritis drug therapy, Arthritis etiology, Diagnosis, Differential, Fever etiology, Humans, Synovial Fluid analysis, Arthritis diagnosis
- Published
- 1987
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.